Preventing resistance through targeted therapy
Chemotherapy is a common treatment strategy for most cases of B-cell lymphoma, but resistance frequently develops and complicates future treatment. In an effort to side-step resistance, our Moon Shot? team is focused on developing novel therapies specifically targeting the fundamental molecular abnormalities of B-cell lymphoma cancer cells. Our targeted therapy approach enables precision treatment, reducing the risk of resistance and the toxic side effects resulting from indiscriminate forms of treatment such as chemotherapy.